Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers
Cian O'Leary1, Grace Murphy1, Yong Yeung1
1Mater Cancer Care Centre, Mater Hospital Brisbane, Brisbane, QLD 4101, Australia.
Abstract:
Non-small-cell lung cancer (NSCLC) is a prevalent and often fatal malignancy. Advancements in targeted therapies have improved outcomes for NSCLC patients in the last decade. Kirsten rat sarcoma virus (KRAS) is a commonly mutated oncogene in NSCLC, contributing to tumorigenesis and proliferation. Though classically difficult to target, recently developed KRAS G12C inhibitors (sotorasib and adagrasib) have now overcome this therapeutic hurdle. We discuss the evidence for these medications, their pitfalls and adverse effects, as well as future directions in this space. Though these medications demonstrate substantial response rates in a heavily pre-treated advanced NSCLC cohort, as phase-3 evidence does not yet demonstrate an overall survival benefit versus standard-of-care chemotherapy, docetaxel. Additionally, these medications appear to have a negative interaction in combination with immunotherapies, with substantially greater hepatotoxicity rates observed. Despite this, it is undeniable that these medications represent an important advancement in targeted and personalised oncological treatment. Current and future trials assessing these medications in combination and through sequencing strategies will likely yield further clinically meaningful outcomes to guide treatment in this patient cohort.
Insights
New KRAS G12C inhibitors offer targeted treatment for non-small-cell lung cancer (NSCLC). While effective in advanced NSCLC, they do not yet show overall survival benefits compared to chemotherapy and have toxicity concerns with immunotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality.
- KRAS mutations are common drivers in NSCLC, historically posing therapeutic challenges.
- Recent development of KRAS G12C inhibitors marks a significant advancement in targeted therapy.
Purpose of the Study:
- To review the clinical evidence for KRAS G12C inhibitors (sotorasib and adagrasib) in NSCLC.
- To discuss the efficacy, limitations, and adverse effects of these novel agents.
- To explore future therapeutic strategies involving KRAS inhibitors.
Main Methods:
- Review of clinical trial data and scientific literature on KRAS G12C inhibitors.
- Analysis of response rates, overall survival, and safety profiles.
- Evaluation of potential drug interactions, particularly with immunotherapy.
Main Results:
- KRAS G12C inhibitors show substantial response rates in pre-treated advanced NSCLC.
- Phase-3 data do not yet confirm an overall survival benefit over docetaxel chemotherapy.
- Combination with immunotherapy shows increased hepatotoxicity, suggesting a negative interaction.
Conclusions:
- KRAS G12C inhibitors represent a significant step in personalized oncological treatment for NSCLC.
- Further research is needed to establish survival benefits and optimize combination/sequencing strategies.
- Careful consideration of toxicity and drug interactions is crucial for clinical application.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle